Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
HER+
What patient population would you target for PHERGain trial enrollment from ASCO2023 in clinical practice?
Related Questions
How would you treat a young premenopausal female with Triple negative inflammatory Breast Cancer who progressed on keynote 522 (received Carboplatin/Taxol/Pembrolizumab) but didn't receive anthracycline portion and has a positive BRCA 2 mutation?
In a patient with local recurrence of breast cancer after mastectomy, how would you sequence adjuvant treatment after wide local resection?
How should we think about endocrine resistance in patients with inherited germline mutations such as BRCA, CHEK2, etc.?
Do you consider post-NAC isolated tumor cells in LNs to be residual disease in TNBC to justify capecitabine?
How do you address iron replacement during breast cancer treatment?
What are your top takeaways from SABCS 2023?
What neoadjuvant chemotherapy regimen would you choose for a triple positive (ER+/PR+/HER2+) cT2N1 G3 breast cancer for an elderly patient (80 y/o)?
Does the degree of hormone receptor positivity influence your decision to perform Oncotype testing?
How would you decide the duration of ovarian suppression in premenopausal females with early stage ER+ breast cancer?
What would you recommend regarding HRT use in a patient with history of HR-, HER2+ breast cancer dealing with post-menopausal symptoms?
